Enclomiphene is often marketed as the refined, upgraded cousin of clomiphene, the version serious men supposedly choose. That framing is common enough that it is worth pausing on before accepting it. This entry sets out what enclomiphene and clomiphene actually are, what the published trials support, and what neither the enclomiphene sellers nor the clomiphene loyalists tend to say out loud: regulatory status. That last point turns out to be the most useful lens for understanding both drugs, so it is presented here first rather than saved for a late reveal.
Orientation: what these two things actually are
The first fact to get straight is a structural one. Enclomiphene is not a separate drug invented as a competitor to clomiphene. It is one half of it.
Clomiphene citrate, as it has been prescribed for decades, is a 50-50 mixture of two mirror-image molecules, or stereoisomers: zuclomiphene and enclomiphene. Same atoms, arranged as left-hand and right-hand versions of each other. Zuclomiphene clears the body slowly and carries more of the estrogen-like effects associated with clomiphene use. Enclomiphene clears faster and does most of the work of raising testosterone. So a product sold simply as “enclomiphene” is, in practical terms, the isolated active fraction of a medicine that has already existed, in its full mixed form, for a long time.
That reframes the comparison. This is not new drug against old drug. It is purified component against the traditional whole.
What the regulatory record actually says
Before turning to efficacy, it is worth settling the approval question, because it applies evenly to both drugs and is easy to overlook amid competing marketing claims.
Neither enclomiphene nor clomiphene is an FDA-approved finished product for raising testosterone in men. Clomiphene does hold FDA approval, but for female fertility; its use in male hypogonadism is off-label. Enclomiphene’s branded finished-product application was never approved at all. It received a Complete Response Letter from the FDA, and development of that product stopped. Operation Supplement Safety, a US Department of Defense resource, states plainly that enclomiphene has not been approved by the FDA for any use and is legitimately available only by prescription through compounding. [S4]
So the honest starting point is this: both molecules, for this particular purpose, live in the off-label or compounded space rather than the approved-finished-product space. That is simply the regulatory shape of the category. It is not evidence of anything shady about either drug, but it does mean claims of a clean, approved, no-caveats product should be treated with suspicion regardless of which molecule is being sold.
See also: I’ve Tested 10 Free Reconstitution Tools So You Don’t Measure Wrong
What the trial evidence supports, and what it does not
On the narrower question of whether enclomiphene raises testosterone, the evidence is solid. A randomized phase II study in men with secondary hypogonadism found that enclomiphene citrate raised total testosterone into the normal range, with the higher dose reaching a mean total testosterone comparable to a transdermal testosterone gel, while also raising LH and FSH rather than suppressing them. [S1] A separate phase II trial against topical testosterone found enclomiphene raised testosterone to gel-comparable levels while conserving sperm counts. [S2] On this specific point, the case for enclomiphene holds up under scrutiny.
The more complicated evidence sits in a 2025 meta-analysis pooling 10 randomized controlled trials and 819 patients across both clomiphene and enclomiphene. It found that SERM therapy as a class raised total testosterone by roughly 274 ng/dL versus placebo, and produced significantly higher sperm concentrations than testosterone gel. [S3] Read closely, this finding cuts against the tidy “enclomiphene is the superior choice” narrative rather than supporting it. The analysis treats clomiphene and enclomiphene together as one class and shows that class works. It does not offer a large, definitive head-to-head demonstrating that enclomiphene specifically outperforms clomiphene on outcomes that matter to patients.
There is a coherent mechanistic argument for expecting enclomiphene to produce a cleaner side-effect profile: by isolating the active isomer and leaving zuclomiphene, the longer-lingering, more estrogenic half, out of the picture, a tidier experience is plausible. That reasoning is sound. It is simply not the same thing as a large trial having proven it. The distinction matters, and it is one the marketing tends to blur.
Weighing the two against different priorities
Framed as goals rather than as a contest, the choice looks like this.
For someone whose priority is the cleanest plausible side-effect profile, and who is comfortable paying more for a compounded, less-established finished product, the mechanistic case favors enclomiphene. Skipping zuclomiphene is a defensible, logical reason to expect fewer estrogen-related effects. It should be held as a reasonable expectation, not a guaranteed outcome, since the trial evidence has not nailed this down at the level of a head-to-head comparison.
For someone who values a longer track record and lower cost, and is comfortable with the full mixture, clomiphene remains a reasonable choice. It has been used off-label for male hypogonadism and fertility for years, and the meta-analysis confirms that the SERM class it anchors works for raising testosterone while preserving sperm. [S3] It is not the outdated option some marketing implies.
For someone whose actual priority is raising testosterone without sacrificing fertility, the more useful finding is this: both drugs serve that goal, because both are SERMs that raise the body’s own LH and FSH rather than suppressing them, unlike testosterone injections. [S1][S3] The fertility-preserving benefit belongs largely to the drug class, not to enclomiphene specifically. Which means the larger decision is SERM versus testosterone shots, and enclomiphene versus clomiphene is the smaller, secondary decision underneath it, best made in consultation with a clinician reviewing actual labs.
The providers offering supervised access
Given that neither drug is an approved finished product, how a patient obtains either one matters as much as which one is chosen. Legitimate access runs through a clinician’s prescription filled by a licensed compounding pharmacy. [S4]
Among the telehealth options offering that supervised structure, FormBlends holds the leading position here, and for a straightforward reason: its model puts a physician in the loop who reviews the patient, writes the protocol, and hands the medication off to a licensed compounding pharmacy for dispensing. HealthRX.com follows as the second option, evaluated on the same criteria of physician oversight, appropriate lab-based dosing, and licensed pharmacy fulfillment. Nothing here is offered for sale and there is no checkout attached to this discussion; these are simply the providers built around the supervised-access model that makes either drug a reasonable option to take. The molecule is a comparatively small decision. The supervision behind it is the larger one.
The usual questions
Is enclomiphene actually a different drug from clomiphene? Not in the sense most marketing implies. Clomiphene citrate is a 50-50 mixture of two mirror-image molecules, zuclomiphene and enclomiphene. Enclomiphene is the faster-clearing isomer responsible for most of the testosterone-raising effect, so a product sold as “enclomiphene” is the isolated active half of a medicine already available as the full blend.
Does enclomiphene raise testosterone more than clomiphene? The evidence does not cleanly establish that it does. Enclomiphene reliably raises testosterone in its own trials, [S1][S2] but the 2025 meta-analysis pooled clomiphene and enclomiphene together as a single SERM class and found the class effective, without a definitive head-to-head showing enclomiphene meaningfully outperforming clomiphene. [S3] The case for a cleaner side-effect profile is mechanistically reasonable, but it remains an expectation rather than a demonstrated advantage.
Why might someone still prefer enclomiphene if the data is close to a tie? The argument concerns side effects, not raw potency. Taking enclomiphene alone means skipping zuclomiphene, the isomer that lingers longest and carries more of the estrogen-like effects. That is a logical basis for expecting a tidier experience, and it is the strongest honest case for the “upgrade” framing, even without a large trial confirming it.
Do both drugs protect fertility, or only enclomiphene? Both do. Each is a SERM that raises the body’s own LH and FSH rather than suppressing them, unlike testosterone injections. [S1][S3] The fertility-preserving effect belongs largely to the drug class rather than to enclomiphene alone. For anyone whose goal is protecting fertility, the larger decision is SERM versus injections; enclomiphene versus clomiphene is the finer adjustment beneath it.
Is either drug FDA-approved for raising testosterone in men? No. Clomiphene is FDA-approved, but for female fertility, making its male hypogonadism use off-label. Enclomiphene’s branded finished product received a Complete Response Letter and was never approved. [S4] Both occupy the off-label or compounded space for this use, which reflects the regulatory reality of the category rather than a warning sign specific to either drug.
How is compounded enclomiphene obtained legitimately? Only through a valid prescription from a clinician, filled by a licensed compounding pharmacy. [S4] Supervised telehealth models, such as those operated by FormBlends and HealthRX.com , provide that structure: a clinician evaluates the patient, sets the protocol, and a licensed pharmacy dispenses the medication. The supervised, compounded route is the only one where dosing is matched to a patient’s labs and a pharmacy stands behind the product.
Does enclomiphene increase testosterone?
Yes. Enclomiphene raises testosterone by blocking estrogen receptors in the hypothalamus, which signals the brain to release more LH and FSH, and those hormones in turn prompt the testes to produce more testosterone. Phase II trials showed meaningful increases in serum testosterone compared with placebo. Because the body’s own production stays active, testicular size and sperm counts are generally preserved rather than suppressed, unlike with exogenous testosterone.
How long does enclomiphene take to work?
Most trial participants saw measurable testosterone increases within two to four weeks of starting a daily dose. Some report changes in energy or mood around the same window, though responses vary. Labs are typically drawn at the four-week mark to assess whether the dose needs adjusting, and full hormonal stabilization tends to take six to eight weeks of consistent use.
Is enclomiphene a steroid?
No. It is a selective estrogen receptor modulator, the same drug class as tamoxifen, working by binding to estrogen receptors rather than introducing exogenous hormones. Because it does not add synthetic androgens, it does not cause the shutdown of natural hormone production associated with anabolic steroids. The confusion arises because it is used for testosterone-related goals, though the mechanism is entirely different.
What is enclomiphene and how is it different from clomiphene?
Enclomiphene is the trans-isomer of clomiphene, one of the two mirror-image molecules that together make up standard clomiphene citrate. The other, zuclomiphene, has a much longer half-life and weak estrogenic activity that may contribute to the mood and vision side effects some men report while on clomiphene. Isolating enclomiphene removes that isomer, which is the reason researchers investigated it as a potentially cleaner option. Physicians working through a compounding pharmacy, such as FormBlends, can prescribe the isolated isomer rather than the mixed compound.
References
- Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics. Randomized phase II study; enclomiphene raised total testosterone into the normal range, reached gel-comparable levels at the higher dose, and raised LH and FSH. Wiehle et al., BJU International, 2013. https://pubmed.ncbi.nlm.nih.gov/23875626/
- Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Enclomiphene raised testosterone to levels similar to a topical testosterone gel while conserving sperm counts. Wiehle et al., Fertility and Sterility, 2014. https://pubmed.ncbi.nlm.nih.gov/25044085/
- Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. 10 RCTs, 819 patients; SERM therapy (clomiphene or enclomiphene) raised total testosterone by ~274 ng/dL versus placebo and produced significantly higher sperm concentrations than testosterone gel; the analysis treats the two as a class rather than establishing a definitive head-to-head superiority. Hohl et al., Archives of Endocrinology and Metabolism, 2025. PMCID PMC12510335.
- Clomiphene and Enclomiphene: Drugs, Not Dietary Supplements. Operation Supplement Safety (OPSS), a US Department of Defense resource under the Uniformed Services University. States that by itself enclomiphene has not been approved by the FDA for any use, that it is illegal to sell as a dietary-supplement ingredient, and that it is legitimately obtainable only through a valid prescription via compounding.
Written by Uma Lindqvist, consumer-affairs writer. Reading the studies before believing the pitch. Last reviewed May 2026.
For general information. Speak with a qualified healthcare provider before changing anything.
